Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2018 2
2019 2
2020 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

4 results
Results by year
Filters applied: . Clear all The following term was not found in PubMed: metastaticparathyroid
Page 1
Preliminary exploration of potential molecular therapeutic targets in recurrent and metastatic parathyroid carcinomas.
Cui M, Hu Y, Bi Y, Wang W, Wang M, Zhang X, Zhang R, Wang P, Su Z, Gao X, Wang J, Li Q, Liao Q, Zhao Y. Cui M, et al. Int J Cancer. 2019 Feb 1;144(3):525-532. doi: 10.1002/ijc.31948. Epub 2018 Dec 3. Int J Cancer. 2019. PMID: 30362515 Free article.
To study whether targeted therapies could be applied in recurrent or metastatic PCs, potential therapeutic targets were identified with next-generation sequencing (NGS). ...A series of recurrent mutant genes was detected as well. Our stud …
To study whether targeted therapies could be applied in recurrent or metastatic PCs, potential therapeutic ta
CD20(+) tumor-infiltrating immune cells and CD204(+) M2 macrophages are associated with prognosis in thymic carcinoma.
Sato J, Kitano S, Motoi N, Ino Y, Yamamoto N, Watanabe S, Ohe Y, Hiraoka N. Sato J, et al. Cancer Sci. 2020 Jun;111(6):1921-1932. doi: 10.1111/cas.14409. Epub 2020 May 8. Cancer Sci. 2020. PMID: 32277550 Free PMC article.
Thymic carcinoma is a rare malignant disease with no standard systemic chemotherapy. ...CD8, CD20 and CD204 positive TIIC in stroma were identified as possible better prognostic biomarkers, considering the heterogeneity of other biomarkers. The present study paves the way …
Thymic carcinoma is a rare malignant disease with no standard systemic chemotherapy. ...CD8, CD20 and CD204 positive TIIC in stroma w …
S100A11 promotes cell proliferation via P38/MAPK signaling pathway in intrahepatic cholangiocarcinoma.
Zhang MX, Gan W, Jing CY, Zheng SS, Yi Y, Zhang J, Xu X, Lin JJ, Zhang BH, Qiu SJ. Zhang MX, et al. Mol Carcinog. 2019 Jan;58(1):19-30. doi: 10.1002/mc.22903. Epub 2018 Oct 21. Mol Carcinog. 2019. PMID: 30182496 Free PMC article.
We previously reported that S100A11 was highly expressed in intrahepatic cholangiocarcinoma (ICC) cells and promoted TGF-beta1-induced EMT through SMAD2/3 signaling pathway. Here, we explored the prognostic role of S100A11 on ICC patients and preliminary molecula
We previously reported that S100A11 was highly expressed in intrahepatic cholangiocarcinoma (ICC) cells and promoted TGF-beta1-induced EMT t …
Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm.
Shuch B, Riggs SB, LaRochelle JC, Kabbinavar FF, Avakian R, Pantuck AJ, Patard JJ, Belldegrun AS. Shuch B, et al. BJU Int. 2008 Sep;102(6):692-6. doi: 10.1111/j.1464-410X.2008.07660.x. Epub 2008 Apr 10. BJU Int. 2008. PMID: 18410444
OBJECTIVE: To evaluate our early experience with neoadjuvant therapy (sunitinib or sorafenib) in advanced renal cell carcinoma (RCC), to explore the effect on both tumour biology and potential for downstaging advanced tumours, as systemic therapy for RCC has …
OBJECTIVE: To evaluate our early experience with neoadjuvant therapy (sunitinib or sorafenib) in advanced renal cell carcinoma (RCC), …